Antibody Therapeutics in Oncology

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies represent a significant advancement in targeted cancer therapy.
• Their success stems from high specificity, efficacy, favorable pharmacokinetics, and standardized manufacturing.
• Antibodies engage the immune system via complement-dependent or antibody-dependent cellular cytotoxicity.

Purpose of the Study:

• To review the mechanisms of action for monoclonal antibody therapeutics in cancer treatment.
• To highlight the advancements in antibody drug conjugates (ADCs) for enhanced cancer therapy.
• To discuss the impact of site-specific conjugation technology on ADC development.

Main Methods:

• Review of scientific literature on monoclonal antibody therapeutics and ADCs.
• Analysis of mechanisms including immune system recruitment and direct tumor cell killing.
• Examination of innovative drug conjugation strategies for ADCs.

Main Results:

• Monoclonal antibodies induce tumor cell death through immune system activation or direct mechanisms like enzyme inhibition and receptor modulation.
• Antibody drug conjugates (ADCs) deliver cytotoxic payloads specifically to cancer cells after antigen binding and internalization.
• Site-specific drug conjugation has led to improved ADC efficacy, safety, and molecular uniformity.

Conclusions:

• Monoclonal antibodies are a versatile and effective class of cancer therapeutics.
• ADCs, particularly those developed with site-specific conjugation, offer a promising future for cancer treatment.
• Continued innovation in antibody-based therapies holds significant potential for advancing oncology care.